Akero Therapeutics, Inc. Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Akero Therapeutics, Inc.Headquarters: South San Francisco, 
                        CA, United States
                    
Employees: 33
CEO: Dr. Andrew  Cheng M.D., Ph.D.

                                    NASDAQ: AKRO
                                
                                            -5.27%
                                            
Market Cap$1.83 Billion

                        USD as of Jan. 1, 2025
                    
                            Market Cap History

Akero Therapeutics, Inc. Categories

United States Healthcare Biotechnology
United States Healthcare United States Biotechnology

Akero Therapeutics, Inc. market capitalization over time

Evolution of Akero Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Akero Therapeutics, Inc.

Top Competitors by Market Capitalization

Industry: Biotechnology

Company	Market Cap (USD)
Novo Nordisk	$622.07 B
Vertex Pharmaceuticals Incorporated	$113.24 B
CSL Limited	$95.75 B
Regeneron Pharmaceuticals, Inc.	$76.33 B
Marinomed Biotech AG	$56.13 B

Sector:

Company	Market Cap (USD)
Lilly	$689.42 B
Novo Nordisk	$622.07 B
UnitedHealth Group	$487.54 B
Johnson & Johnson	$353.05 B
AbbVie	$301.60 B

Detailed Description

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date	Sept. 30, 2024
Revenue TTM	$0
EBITDA	$-269,265,984
Gross Profit TTM	$0
Profit Margin	0.00%
Operating Margin	0.00%
Quarterly Revenue Growth	%